Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13R?2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
Stock Information for Mustang Bio Inc.
Loading
Please wait while we load your information from QuoteMedia.